Halifax portfolio firm Envision Pharma buys ProScribe.
6 February 2014 - US technology and scientific communication company Envision Pharma Group, backed by buyout firm The Halifax Group, said it had purchased Australian medical writing specialist ProScribe Medical Communications, without specifying the price.
ProScribe, which was founded by Karen Woolley and Mark Woolley, will become Envision Pharma's fifth division, named Scientific Solutions.
The target's founders will join the buyer's senior management and will continue to lead the ProScribe team, Envision Pharma said.
The deal expands Envision Pharma's footprint and capabilities within the strategically important Asia-Pacific region, enabling it to cater to a pharmaceutical and biotechnology sector that is global in nature, the buyer said.
ProScribe has locations in Australia, China and Japan and serves academia, biopharma and medical device firms.
Sector: Business and Consumer Services, Media
Target: ProScribe Medical Communications
Buyer: The Halifax Group, Envision Pharma Group
Vendor: Mark Woolley, Karen Woolley
Type: Corporate acquisition, LBO
|Printer friendly Cite/link Email Feedback|
|Publication:||M & A Navigator|
|Date:||Feb 6, 2014|
|Previous Article:||Whitmore expands product offering with buy of Fluid Defense.|
|Next Article:||Croatia to renew attempt to divest Croatia Airlines.|